Pds biotech reschedules key opinion leader roundtable addressing current and future treatments for recurrent/metastatic hpv-positive hnscc and the potential application of pds0101

Princeton, n.j., sept. 25, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (pds biotech or the company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced that its key opinion leader (kol) roundtable on addressing current and future treatments for recurrent/metastatic human papillomavirus (hpv)-positive head and neck squamous cell carcinoma (hnscc) and the potential application of pds0101 will now take place on tuesday, october 3, 2023, from 8:00 – 9:00 am edt, due to a scheduling conflict. the event was originally scheduled for wednesday, september 27, 2023.
PDSB Ratings Summary
PDSB Quant Ranking